as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients wi...
Table 2. Response to treatment by genotype for 222 patients with multiple myeloma treated with ABCM or CVAMP/HDM Empty CellGSTP1 105 genotype Empty Cell Empty Cell Empty CellIle/Ile, no.(%)Ile/Val, no.(%)Val/Val, no.(%)Total, no.(%)P* ABCM arm Plateau reached Yes 32 (66) ...
Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone as First-Line Therapy for Multiple Myeloma In patients with multiple myeloma (MM) who may ultimately receive active therapy, the combination of VAD (vincristine, doxorubicin, and dexamethasone) has ... Mohamad,Hussein - 《Clinic...
Kyle. (2006) Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma. Mayo Clinic Proceedings 81 , 1047-1053 /Lacy, MQ, Dispenzieri, A, Gertz, MA, Greipp, PR, Gollbach, KL, Hayman, SR (2006) Mayo clinic consensus statement for the use of bisphosphonates in ...
Introduction: Several treatment programs are available for the initial management of patients with multiple myeloma, with no clear documented advantage(s) of one regimen over the others in terms of time to progression (TTP) or overall survival (OS). Materials and Methods: A questionnaire was maile...
Multiple myeloma is the most common indication for high-dose chemotherapy with autologous stem cell support (ASCT) in North America today. Stem cell procurement for ASCT has most commonly been performed with stem cell mobilization using colony-stimulating factors with or without prior chemotherapy. The...
The approval of belantamab mafodotin-blmf (Blenrep) for patients with refractory multiple myeloma marks the first therapy directed at B-cell maturation antigen (BCMA), a target of robust research interest, to reach clinical practice. The FDA granted an accelerated approval for the agent on Aug...
Considerable progress has been recently made in the treatment of elderly patients with multiple myeloma (MM). In Europe the combination of thalidomide with melphalan and prednisone and of bortezomib with melphalan and prednisone are 2 standards of care for frontline therapy for elderly patients. In ...
Current standards of care for first-line treatment of multiple myeloma are evolving rapidly because of the introduction of regimens based on novel agents with unique mechanisms of action: the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. These regimens are bec...
(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable. "Recently developed drugs...